Shenzhen Potential Technology has four rounds of financing in one and a half years: AI+ molecular simulation accelerates the upgrading of traditional industries

The Paper learned that on January 17, Beijing Shenshi Technology Co., Ltd. (hereinafter referred to as "Shenshi Technology") announced the completion of tens of millions of dollars in Series B financing. So far, Shenzhen Potential Technology has completed four consecutive rounds of financing in 18 months.

This round of financing is jointly led by Source Code Capital and Qiming Venture Capital, and the old shareholders Hillhouse Venture Capital and Matrix Partners continue to increase their size. It is reported that the financing funds will be used to continuously attract top talents in the industry, so as to deepen the construction of micro-scale industrial design platforms, as well as the landing of related technologies in scenarios such as drugs and material design.

According to the company's official website, Shenshi Technology was established in 2018, is committed to solving micro-scale industrial design problems with a new generation of molecular simulation technology, and takes the creation of a simulation research and development platform that effectively serves pharmaceutical companies, material suppliers and scientific research institutions as the main business direction. The company's core team is led by E weinan, an academician of the Chinese Academy of Sciences, and others, mainly from world-class universities, scientific research institutions and enterprises, and the scientific research team is composed of dozens of outstanding young scientists in many fields such as physical modeling, numerical algorithms, machine learning, high-performance computing, and drug and material computing.

It is worth noting that Shenshi Technology is the forerunner of the AI+Science scientific research paradigm, and its pioneering "multi-scale modeling + machine learning + high-performance computing" paradigm has achieved a breakthrough in the unification of accuracy and efficiency in multi-scale molecular simulation.

With a new generation of molecular simulation technology, the core members of the Shenzhen Potential Technology team have won the ACM Gordon Bell Award, the highest award in the field of high-performance computing in 2020. The Golden bell prize is known as the Nobel Prize in supercomputing. The relevant work was also elected as the top ten scientific and technological progress in China in 2020 and the top ten scientific and technological progress in global artificial intelligence in 2020 selected by academicians of the two academies.

Up to now, Shenzhen Potential Technology has expanded the technical capabilities of AI+ molecular simulation to the efficient calculation of quantum mechanics accuracy of billions of atoms, and on the basis of this technical idea, in view of the diversified simulation research and development needs from the underlying mathematical model to the simulation tools under computer science, and then to the specific scenarios of chemistry, biology, materials and so on, the Lebesgue scientific computing platform, Hermite drug design platform and The Bohrium microcomputing and design platform have been launched. Together, they form the matrix of microscale industrial design platform of Deep Potential Technology.

Through these cost-effective new productivity tools, Shenshi Technology is committed to liberating the productivity of scientific research and industrial design, and accelerating the transformation and upgrading of traditional industries.

For example, in the field of medicine, Shenshi Technology has joined hands with a number of customers to combine the computational paradigm of physical modeling + AI with preclinical drug research and development, and through hermite Uni-FEP, Uni-Fold, RiD and other modules, the free energy perturbation theory, molecular dynamics, enhanced sampling algorithm and high-performance computing are combined to accurately predict protein structure and conformational changes, and efficiently evaluate the binding free energy of proteins and ligands with chemical precision. Provide efficient and accurate theoretical guidance for drug developers to improve the efficiency of drug design and optimization.

In addition, in the field of new energy, Shenshi Technology and CATL have reached a cooperation to jointly build a joint laboratory to jointly expand the future space for the development of cutting-edge technologies in the field of new energy with a more efficient calculation-driven material research and development model.

Sun Weijie, founder and CEO of Shenshi Technology, said this time that AI+Science as a new R & D paradigm has become a hot spot in the field, we practitioners should continue to define and solve key problems in the industry, expand the boundaries of technological productivity, use all advanced computing methods to improve the efficiency of computing simulation, and transform the research and development of micro-scale industrial fields from large-scale trial and error experiments to a new paradigm of "computational design - experimental verification" as soon as possible, providing micro-scale industrial design infrastructure for the evolution of human civilization.